Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
21 déc. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe
16 déc. 2022 16h01 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Pipeline Update
14 déc. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
08 déc. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Host Annual Research and Development Day in New York
06 déc. 2022 09h00 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company today announced that it will host its...
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application
01 déc. 2022 17h34 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
07 nov. 2022 16h01 HE
|
Y-mAbs Therapeutics, Inc
Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022DANYELZA marketing authorization granted in Israel; regulatory filing...
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022
02 nov. 2022 16h01 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended...
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
28 oct. 2022 15h33 HE
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...